| Name | Title | Contact Details |
|---|
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Protoms Radiance 330 Proton Therapy System is compact, customizable, and has the industrys fastest return on investment.
Stone and Magnanini is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our emtelliPro NLP engine transforms difficult-to-use, narrative medical text into valuable and actionable insights. Enable innovation. Improve competitiveness. Drive performance.